ReviewFrontiers in endocrinology2026
Management of pregnancy in patients with Graves' disease secondary to alemtuzumab: a case series and literature review.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Alemtuzumab treatment for multiple sclerosis frequently induces Graves' disease (GD), characterized by common coexistence of stimulating and blocking anti-thyrotropin receptor autoantibodies (TRAb), causing fluctuations of thyroid function. Alemtuzumab-induced TRAb-positive hypothyroidism is also common. These conditions are challenging to manage during pregnancy, considering the imperative necessity to maintain euthyroidism to minimize risks for both pregnancy and fetal/neonatal outcomes. Methods: We reviewed the clinical course and therapeutic management of four pregnant women affected with alemtuzumab-induced GD or TRAb-positive hypothyroidism followed at our Institution, and seven additional cases published in literature. Results: At our institution two patients with alemtuzumab-induced GD (one diagnosed before pregnancy, the other during the third trimester) showed a good control of thyroid function on anti-thyroid drugs (ATD). Two women had alemtuzumab-induced TRAb positive hypothyroidism; during pregnancy thyroid function was partially controlled with levothyroxine (LT4) alone in one case, and fully controlled with block and replace (ATD and LT4) in the other case. No pregnancy or fetal/neonatal negative outcomes were observed, except for preterm delivery of a healthy baby in Case 3, due to emergency cesarean section for pre-eclampsia progressing to HELLP syndrome. The literature search showed seven additional cases of pregnant women with alemtuzumab-induced GD (N = 5) or TRAb-positive hypothyroidism (N = 2), mainly diagnosed during gestation, especially in the first trimester. Six newborns developed transient thyroid dysfunction, often requiring treatment and later resolved. Conclusion: The clinical management of alemtuzumab-induced thyroid dysfunction during pregnancy is challenged by frequent difficult maternal biochemical thyroid control and TRAb-mediated fetal/neonatal thyroid dysfunction. These patients need to be managed in a specialist setting, with close monitoring of maternal thyroid function and fetal/neonatal parameters, especially in cases with high TRAb titers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.